US 12,434,072 B2
Methods and systems for neural stimulation via visual, auditory and peripheral nerve stimulations
Zachary John Hambrecht Malchano, Boston, MA (US); and Martin Warren Williams, San Francisco, CA (US)
Assigned to COGNITO THERAPEUTICS, INC., Cambridge, MA (US)
Filed by Cognito Therapeutics, Inc., Cambridge, MA (US)
Filed on Apr. 22, 2024, as Appl. No. 18/642,364.
Application 18/642,364 is a continuation of application No. 16/919,975, filed on Jul. 2, 2020, granted, now 12,383,759.
Application 16/919,975 is a continuation of application No. 16/427,276, filed on May 30, 2019, granted, now 10,702,705, issued on Jul. 7, 2020.
Application 16/427,276 is a continuation of application No. 15/816,238, filed on Nov. 17, 2017, granted, now 10,307,611, issued on Jun. 4, 2019.
Claims priority of provisional application 62/431,725, filed on Dec. 8, 2016.
Claims priority of provisional application 62/431,720, filed on Dec. 8, 2016.
Claims priority of provisional application 62/431,698, filed on Dec. 8, 2016.
Claims priority of provisional application 62/431,702, filed on Dec. 8, 2016.
Claims priority of provisional application 62/423,536, filed on Nov. 17, 2016.
Claims priority of provisional application 62/423,452, filed on Nov. 17, 2016.
Claims priority of provisional application 62/423,569, filed on Nov. 17, 2016.
Claims priority of provisional application 62/423,598, filed on Nov. 17, 2016.
Claims priority of provisional application 62/423,532, filed on Nov. 17, 2016.
Claims priority of provisional application 62/423,557, filed on Nov. 17, 2016.
Claims priority of provisional application 62/423,517, filed on Nov. 17, 2016.
Prior Publication US 2024/0269481 A1, Aug. 15, 2024
Int. Cl. A61N 5/06 (2006.01); A61B 5/00 (2006.01); A61B 5/16 (2006.01); A61B 5/377 (2021.01); A61B 5/378 (2021.01); A61B 5/38 (2021.01); A61M 21/00 (2006.01); A61N 1/04 (2006.01); A61N 1/36 (2006.01); G02C 11/00 (2006.01); H05B 47/105 (2020.01); A61B 3/113 (2006.01); A61B 5/024 (2006.01); A61B 5/05 (2021.01); A61B 5/375 (2021.01); A61B 5/398 (2021.01); A61N 1/05 (2006.01)
CPC A61N 5/0622 (2013.01) [A61B 5/0036 (2018.08); A61B 5/16 (2013.01); A61B 5/377 (2021.01); A61B 5/378 (2021.01); A61B 5/38 (2021.01); A61B 5/4088 (2013.01); A61B 5/4836 (2013.01); A61M 21/00 (2013.01); A61N 1/0456 (2013.01); A61N 1/36025 (2013.01); A61N 1/36036 (2017.08); A61N 1/36082 (2013.01); A61N 1/36092 (2013.01); A61N 1/36132 (2013.01); A61N 5/0618 (2013.01); G02C 11/10 (2013.01); H05B 47/105 (2020.01); A61B 3/113 (2013.01); A61B 5/024 (2013.01); A61B 5/05 (2013.01); A61B 5/163 (2017.08); A61B 5/168 (2013.01); A61B 5/375 (2021.01); A61B 5/398 (2021.01); A61B 5/4848 (2013.01); A61B 5/6803 (2013.01); A61M 2021/0027 (2013.01); A61M 2021/0044 (2013.01); A61M 2021/0072 (2013.01); A61M 2205/3375 (2013.01); A61N 1/0551 (2013.01); A61N 2005/0626 (2013.01); A61N 2005/0627 (2013.01); A61N 2005/0629 (2013.01); A61N 2005/0648 (2013.01); A61N 2005/0652 (2013.01); A61N 2005/0659 (2013.01); A61N 2005/0661 (2013.01); A61N 2005/0662 (2013.01); A61N 2005/0663 (2013.01); A61N 2005/0667 (2013.01); G02C 2200/10 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method for treating mild cognitive impairment or Alzheimer's disease or benefiting a cognitive function of a brain of a subject in need thereof via a system, the method comprising:
(a) using a first light source to generate a first light pulse and using a second light source to generate a second light pulse, wherein said first light source or said second light source comprises a filtering component configured to selectively transmit a portion of an initial spectral range of the first light pulse or the second light pulse;
(b) determining an attention level of the subject by:
(i) performing eye tracking of an eye of the subject via a feedback sensor; or
(ii) determining an orientation of at least one of a head or a body of the subject; and
(c) emitting the first light pulse and the second light pulse to the subject, wherein the first light pulse and the second light pulse are emitted at a 40 Hertz (Hz) frequency, thereby slowing a progression of mild cognitive impairment or Alzheimer's disease, or thereby benefiting the cognitive state or function of the brain of the subject; wherein the determining the attention level of the subject comprises comparing, via a feedback monitor, a direction or a movement of an eye of the subject to a historical eye direction or an eye movement of the subject based on a threshold.